Stepan Company (NYSE:SCL) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed several negative factors, including a significant EPS miss, higher pre-operating expenses, and macroeconomic challenges impacting demand. Despite some positive elements like dividend increases and free cash flow improvements, the refusal to provide guidance and unclear management responses contribute to uncertainty. The market cap indicates a moderate reaction is likely, leading to a predicted stock price decrease of -2% to -8% over the next two weeks.
Key Financial Performance
Adjusted EBITDA (Q4 2024) $35 million, down 7% year-over-year due to lower global sales volume and higher pre-operating expenses.
Adjusted Net Income (Q4 2024) $2.8 million, or $0.12 per diluted share, a 63% decrease year-over-year mainly due to $4.4 million of higher pre-operating expenses and a $2.9 million one-time tax reserve.
Global Sales Volume (Q4 2024) Down 1% year-over-year, with double-digit growth in surfactants offset by softer demand in polymers.
Cash from Operations (Q4 2024) $68 million.
Free Cash Flow (Q4 2024) $32 million.
Adjusted EBITDA (Full Year 2024) $187 million, a 4% increase year-over-year despite one-time costs and higher pre-operating expenses.
Adjusted Net Income (Full Year 2024) $50.5 million, flat year-over-year.
Free Cash Flow (Full Year 2024) $39 million, up $125 million year-over-year due to normalized capital investments and decreased working capital.
Pretax Cost Savings (Full Year 2024) $48 million, achieved through supply chain and workforce productivity actions.
Surfactant Net Sales (Q4 2024) $379 million, a 3% increase year-over-year driven by higher selling prices and sales volume.
Polymer Net Sales (Q4 2024) $130 million, a 12% decrease year-over-year due to lower selling prices and sales volume.
Specialty Product Net Sales (Q4 2024) $17 million, a 10% increase year-over-year due to higher sales volume and selling prices.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Products: The company is excited about the new products being introduced in the growing spray foam end market.
Market Expansion: In 2024, the company grew double digits in oilfield and in construction and industrial solution businesses. Additionally, the agricultural business grew volume 30% in the second half of 2024.
Operational Efficiencies: The company recognized $48 million in pretax cost savings during 2024, mainly through disciplined efforts in supply chain and workforce productivity.
New Facility: Construction of the new constellation production facility in Pasadena, Texas, is nearing completion, with startup expected in Q1 2025.
Strategic Shifts: The company is focusing on customer acquisition with tier two and three customers, which is a key priority for profitable growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Earnings Miss: Stepan Company reported an EPS of $0.1462, missing expectations of $0.45.
Pre-Operating Expenses: Higher pre-operating expenses of $4.4 million related to the new Pasadena site negatively impacted earnings.
Tax Proceeding Reserve: A one-time tax proceeding reserve in Latin America resulted in an additional $2.9 million expense.
CEO Transition Costs: The CEO transition impacted quarterly results by $2.8 million.
Polymers Demand: Softer demand in the polymers segment, particularly a 9% decline in sales volume, was attributed to sluggish global macroeconomic conditions and competitive pressures.
Global Economic Conditions: Overall construction activity and a higher interest rate environment contributed to sluggish demand in the polymers market.
Supply Chain Challenges: Investments were made to improve supply chain resiliency, indicating existing challenges.
Inflation Impact: Overall inflation affected operational costs despite achieving $48 million in pretax cost savings.
Foreign Currency Translation: Foreign currency translation negatively impacted net sales by 3% in the surfactant segment.
Asia Fraud Incident: Corporate expenses increased due to the Asia fraud event.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Customer Acquisition: In 2024, Stepan Company added over 1,700 new customers, focusing on tier two and three customers as a key growth channel.
End Market Diversification: The company achieved double-digit growth in oilfield and construction and industrial solution businesses, with a 30% volume increase in the agricultural business in the second half of 2024.
Cost and Operational Excellence: Recognized $48 million in pretax savings in 2024 despite one-time unfavorable events, focusing on supply chain resiliency.
New Facility in Pasadena, Texas: Construction of the new constellation production facility is nearing completion, expected to start up in Q1 2025, with full contribution run rate anticipated in the second half of 2025.
Adjusted EBITDA Growth: The company expects adjusted EBITDA to improve across all reporting segments in 2025.
Free Cash Flow: Positive free cash flow is anticipated in 2025.
Polymers Volume Growth: The company is optimistic about increasing Polymers volumes as they execute innovation and growth plans.
Surfactant Business Growth: Continued growth is expected in the Surfactant business within key strategic end markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends Paid: During the fourth quarter of 2024, the company paid $8.7 million in dividends to shareholders.
Quarterly Cash Dividend: The Board of Directors declared a quarterly cash dividend on Stepan common stock of $0.385 per share, payable on March 14, 2025.
Consecutive Dividend Increases: Stepan has paid and increased its dividend for 57 consecutive years.
Free Cash Flow: Free cash flow for the year was positive at $39 million.
Capital Investments for Dividends: During the year, the company deployed $34 million for dividends.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How much more runway do you see in Ag through the pounds of 2025?
A:We expect double-digit growth to continue in Ag, especially after a strong second half with 30% growth overall.
Q:Would you characterize the challenges in polymers as across the board or are there any pockets of strength?
A:There are pockets of strength in polymers, particularly in specialty products and China, despite sluggish demand in other areas.
Q:Should price mix be kind of flattish or could it be positive for full year 2025?
A:We are seeing a positive price mix due to growth in tier two and tier three customers, and we expect this trend to continue.
Q:Can you help us level set the starting point for 2025 EBITDA?
A:I’m not gonna provide guidance, but we had significant one-time events in 2024 that we aim to avoid in 2025.
Q:Are there any other one-time or unusual factors we need to keep in mind as we’re thinking about Q1?
A:The only one-timer will be Pasadena; we are seeing a good start to 2025.
Q:Can you give us guidance on how to look at interest expense and depreciation through 2025?
A:We provided guidance for depreciation, but specifics will depend on the timing of production ramp-up.
Q:What is your sensitivity to recurrences in the euro, the Mexican peso, and the Brazilian real?
A:The main risk is the euro; the impact from Mexico and Brazil is not material.
Q:Can you talk about your expectations in the construction market in China?
A:Our polymers business in China is diversified and not solely focused on construction, so we are not heavily exposed to current issues in that market.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on 2025 EBITDA and the implications of the Pasadena facility ramp-up, indicating that they would provide more details in April.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Asia fraud
CEO transition
Sales volume
Specialty Products
Stepan
Surfactant Specialty
Texas tax
area
bridge decrease
constellation
currency translation
customer mix
demand polymer
demand pressure
effort end
event
investor
margin recovery
officer
plan
presentation slide
proceeding reserve
product customer
productivity effort
reserve Latin
resiliency
sale increase
session
specialty product
star
tax proceeding
thirteen
tier
volume product
SCL Transcript
Stepan Company (SCL) Q3 2025 Earnings Call Transcript
Unknown10-29
Despite some positive aspects like increased dividends and specialty products growth, the overall sentiment is negative due to significant declines in adjusted net income and EBITDA, margin pressures, and unclear management responses regarding future plans. The company is also dealing with challenging raw material costs and competitive pressures. The market cap suggests a moderate reaction, leading to a likely negative stock price movement of -2% to -8% over the next two weeks.
Stepan Company (SCL) Q2 2025 Earnings Call Transcript
Unknown7-30
The earnings call summary presents mixed signals: strong growth in polymers and specialty products, yet challenges in surfactants and negative free cash flow. The Q&A reveals concerns about raw material costs and asset optimization, but also highlights potential growth from pricing adjustments and new initiatives. The market cap suggests moderate volatility, so the stock price is likely to remain stable, with a neutral sentiment in the short term.
Stepan Company (SCL) Q1 2025 Earnings Call Transcript
Unknown4-29
The earnings call presents mixed signals. While there is strong financial performance with increased EBITDA and net income, free cash flow is negative, and there are concerns about tariffs and economic challenges. The growth in Surfactants and Specialty Products is positive, but the Polymers segment faces pricing pressures. The Pasadena facility's delayed positive contribution and cautious guidance temper enthusiasm. Given the company's market cap, the stock is likely to experience a neutral movement, as positive aspects are balanced by negative factors.
Stepan Company (NYSE:SCL) Q4 2024 Earnings Call Transcript
Unknown2-20
The earnings call revealed several negative factors, including a significant EPS miss, higher pre-operating expenses, and macroeconomic challenges impacting demand. Despite some positive elements like dividend increases and free cash flow improvements, the refusal to provide guidance and unclear management responses contribute to uncertainty. The market cap indicates a moderate reaction is likely, leading to a predicted stock price decrease of -2% to -8% over the next two weeks.
SCL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
